Overview

A Study to Evaluate Plasmin for the Creation of a Posterior Vitreous Detachment (PVD)

Status:
Terminated
Trial end date:
2007-06-01
Target enrollment:
Participant gender:
Summary
Plasmin is expected to create a posterior vitreous detachment (PVD) when injected directly into the eye. The pharmacological creation of a PVD may be beneficial in helping to treat a variety of conditions.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Bausch & Lomb Incorporated
Treatments:
Fibrinolysin